Rheumatology Advisor4d
Tremfya Approved for Moderately to Severely Active Crohn Disease
The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Healthline6d
Do You Need to Treat Asymptomatic Crohn’s Disease?
Silent Crohn’s disease may have little or no symptoms. It's important to monitor disease activity and treat the condition to ...